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Abstract
Background: Mutations in the integral membrane protein 2B [1], also known as BRI2 [2], a type II trans-membrane domain
protein cause two autosomal dominant neurodegenerative diseases, Familial British and Danish Dementia [3]. In these
conditions, accumulation of a C-terminal peptide (ABri and ADan) cleaved off from the mutated precursor protein by the
pro-protein convertase furin [4], leads to amyloid deposition in the walls of blood vessels and parenchyma of the brain.
Recent advances in the understanding of the generation of amyloid in Alzheimer’s disease has lead to the finding that BRI2
interacts with the Amyloid Precursor Protein (APP), decreasing the efficiency of APP processing to generate Ab [5,6,7]. The
interaction between the two precursors, APP and BRI2, and possibly between Ab and ABri or ADan, could be important in
influencing the rate of amyloid production or the tendency of these peptides to aggregate.
Methodology/Principal Findings: We have generated the first BRI2 Danish Knock-In (FDDKI) murine model of FDD,
expressing the pathogenic decamer duplication in exon 6 of the BRI2 gene. FDDKI mice do not show any evident abnormal
phenotype, with normal brain histology and no detectable amyloid deposition in blood vessel walls or parenchyma.
Conclusions/Significance: This new murine mouse model will be important to further understand the interaction between
APP and BRI2, and to provide insights into the molecular basis of FDD.
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Introduction
BRI2 is a type II trans-membrane protein of unknown function.
The BRI gene belongs to a multigene family comprising at least
three homologues in both mice and humans, BRI1, BRI2 and BRI3
(also referred to as ITM2A, ITM2B and ITM2C,o rE25A, E25B
and E25C, respectively) [1,2,3,8,9]. It possesses a BRICHOS
domain, a conserved motif common to members of the BRI,
ChM-I, SP-C and CA11 protein families, thought to have a role in
the targeting of the respective proteins to the secretory pathway or
to intracellular processing [10]. Proteins sharing the BRICHOS
motif are dissimilar, and associate with a diverse range of
phenotypes, varying from dementia to cancer and respiratory
distress.
BRI2 was first described in relation to Familial British Dementia
(FBD) [2], an autosomal dominant neurodegenerative disease
characterized by the early onset of personality changes, memory
and cognitive deficits, spastic rigidity and ataxia. In FBD, a C-
terminal 34 amino acid (aa) peptide of BRI2 accumulates as
amyloid, leading to severe amyloid angiopathy of the brain and
spinal cord with perivascular amyloid plaque formation, paren-
chymal plaques affecting the limbic areas, cerebellum, cerebral
cortex, neurofibrillary tangles of hippocampal neurons and
periventricular white matter changes [11]. Familial Danish
Dementia (FDD), previously known as heredopathia ophthalmo-
otoencephalica, is an autosomal dominant disease characterized
by the accumulation of an amyloidogenic C-terminal 34 aa
peptide of BRI2 [3]. FDD is characterized by early onset cataracts,
deafness, progressive ataxia and dementia [3,12]. Neuropatholog-
ical examination of patients with FDD shows diffuse brain atrophy
with a particularly severe involvement of the cerebellum, cerebral
cortex and white matter, as well as the presence of very thin and
almost demyelinated cranial nerves, and widespread amyloid
angiopathy in the small blood vessels and capillaries of the
cerebrum, choroid plexus, cerebellum, spinal cord and retina. In
FDD, parenchymal compact plaques are consistently absent,
whereas neurofibrillary tangles (NFTs) are the major histological
finding in the hippocampus [3,12].
BRI2 is physiologically cleaved, at the C-terminus, by furin, a
calcium-dependent serine endoprotease, producing a 23 aa soluble
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BRI2 gene located on chromosome 13q14 [2,8]. In FBD, a single
base substitution at the stop codon of BRI2 generates a longer open
reading frame, resulting in a larger, 277 aa precursor (BRI2-ABri,
compared to the 266 aa long normal protein) [2]. In FDD, a
decamer duplication in the 39 region of the BRI2 gene, right before
the stop codon, leads as well to the production of a longer, 277 aa
protein (BRI2-ADan) [3]. The genetic defect is different, but the
outcome is the same: the generation of a longer 34 aa C-terminal
fragment, ABri in FBD and ADan in FDD, which accumulates as
amyloid [2].
Several neuropathological features are common to FBD, FDD
and Alzheimer’s disease (AD): amyloid deposition and neurode-
generation in the central nervous system (CNS), accumulation of
complement proteins and their pro-inflammatory activation
products, including iC3b, C4d, Bb, and C5b-9, neurofibrillary
pathology and hyperphosphorylated tau [12,13,14]. Furthermore,
in FDD, Alzheimer’s Ab co-deposits with ADan, mainly in
vascular and perivascular amyloid lesions and less in parenchymal
preamyloid deposits [12], while compact plaques are not frequent
[2,12,15].
More recently, a new link between BRI2 and Ab has been
found. It has been shown that BRI2 binds APP in a region
comprising the extracellular juxtamembrane domains of both
proteins, in a cis fashion [5,6,7]. This interaction leads to
interference on the physiological processing of APP: BRI2 restricts
the docking of c-secretase to APP and the access of a- and b-
secretases to their cleavage site on APP itself. The overall result of
this interaction is the reduction of the amyloidogenic processing of
APP, without a direct inhibition of the general activity of the
secretases [5]. BRI2 maturation is required for this function. In
fact, only mBRI2 (and not the immature precursor) binds mature
APP and inhibits its processing on the plasma membrane and in
endocytic compartments [16]. Matsuda et al have further shown
that BRI3, a member of the BRI family, binds and inhibit the
action of a- and b-secretases on APP [17]. Others have argued
that the BRI2-23 wild type C-terminal peptide, released from
BRI2 by furin/furin-like cleavage, can inhibit Ab aggregation in
vitro [18].
The interaction between these two amyloidogenic proteins can
be of interest, especially for the design of new therapeutic strategies
for AD and FBD/FDD. To this end, the processing of the BRI2
precursor, both in the wild type allele and its mutant form must be
understood. Transgenic mice bearing the British or Danish
mutations have been generated, and are under investigation as
models of dementias and cerebral amyloid angiopathies [19,20]. A
transgenic FDD model which over-expresses the Danish mutant
form of BRI2 shows amyloid deposition in the walls of blood
vessels of the cerebrum and cerebellum, parenchymal amyloid
deposition and reactive gliosis, ADan amyloidosis and some signs
of cerebellar ataxia [20]. Transgenic over-expression of human
mutant genes has been extensively used to generate mouse models
for human neurodegenerative disorders due to the need of over-
expressing enough amount of the mutant protein in order to
observe a phenotype. It is however possible that some disorders
may, at least partially, be due to loss of function rather than a gain
of toxic function due to mutations. If this were the case, a
transgenic approach would be counterproductive. Therefore, we
have reasoned that models reproducing the genetics of human
pathologies may be worth studying since they may unveil
important disease mechanisms that a transgenic approach may
miss or, possibly, hide. Thus, we have generated a genetically
faithful model of FDD by introducing the pathogenic human
mutation in the mouse BRI2 gene by a knock-in technology. Here,
we describe the generation of this Knock-In murine model of FDD
(FDDKI) and its initial characterization.
Materials and Methods
Ethics Statement
Mice were maintained on a C57BL/6 background for several
generations (at least 15). Mice were handled according to the
Ethical Guidelines for Treatment of Laboratory Animals of Albert
Einstein College of Medicine. The procedures were described and
approved in animal protocol number 20040707.
FDDKI Mice Construction
To clone the ADan mutation allele, a fragment obtained form
BAC (containing mouse BRI2 genome) was amplified by PCR with
the following primers:
Fw: 59-cccAAGCTTtttttttttttttttaaagacaac-39; Rev: 59-gggAA-
GCTTgaagtggtcagcagggag-39, obtaining a 7536 bp fragment,
flanked by 2 HindIII sites, and comprising part of Intron 2 to a
39UTR region, up to 3850 bp from the BRI2 stop codon. Such a
fragment was cloned into a pBS vector, into HindIII sites (pBS-
Ex3-6 HindIII), and used as a template for subsequent cloning.
A 340 bp fragment containing the ADan (duplication 786–795
of cDNA) mutation, plus a humanizing substitution aRg
(accRgcc=ThreonineRAlanine) at the 12
th codon of exon 6,
was obtained by serial PCRs, using pBS-Ex3-6 HindIII as a
template. The final external primers contained restriction sites for
HincII (59) and EcoRI (39). The mutated fragment (HincII-ADan-
EcoRI) was inserted into the SmaI and EcoRI sites of a pBS vector
yielding pBS-ADan0.3.
Subsequently, 2 EcoRI-EcoRI and EcoRI-XhoI fragments (2.6 kbp
total) were cut from the template and added 39, in tandem, to pBS-
ADan0.3, generating pBS-ADan2.9, containing the Right Arm
(RA) fragment of the construct.
A NotI-XhoI fragment from pBS-ADan2.9, comprising the RA,
was inserted into NotI and SacII sites of a Soriano PGK-Neo-dTA
vector (blunt-ended by the SacII and XhoI digestion followed by
treatment of T4-exonuclease and Klenow polymerase respectively)
at 59of the Neo cassette. The XhoI site was reconstituted upon
ligation of the fragment into the vector.
The construct’s Left Arm was extracted from the template with
EcoRI and HincII, generating a 1.1 kbp into Intron 5 up to the
corresponding HincII site, 59 of Exon 6 (start of Right Arm). The
fragment was thus inserted into the PGK-Neo-dTA vector at 39 of
the Neo cassette and 59 of the dTA cassette.
The resulting construct was thus:
---Right Arm-LoxP1-PGK-Neomycin cassette-LoxP2-Left Arm-
dTA cassette---.
The resulting construct was linearized with SalI and purified
prior to injection in ES cells strain 129 by electroporation. ES
culture was performed on feeder layer, and further electroporation
and handling was also performed according to the methodology
employed at Dept of Cell Biology, Albert Einstein College of
Medicine, and according to Wakayama et al. [21]. In particular,
after electroporation, ES cells were re-plated in 55 cm
2 dishes and
let grow until visible clones would appear. Clones were then
picked and transferred to 96 well plates in triplicates. Triplicates
were either screened by PCR or frozen for subsequent use and
further analysis.
Homologous recombinants were selected with G418 (200 mg/
ml) and dTA exclusion.
Injection of the two Danish ES cell clones into C57BL/6J
blastocysts was performed at the Albert Einstein College of
Medicine gene-targeting facility, according to the current facility
FDD Knock-In Mice
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PCR Analysis
The PCR screening was performed using the Expand Long
Template PCR System (Roche-applied-Science) with Betaine,
according to the manufacturer instructions. PCR analysis of
recombinant ES cells and mice was conducted with the following
primers and digestion strategies to identify the correct recombi-
nant clones and strains:
ES cells:
Left arm:
Genomic primer: 59-CAGTCCTACCTTATCCATGAGCAC-
39
Neo cassette primer: 59- CTTCCTCGTGCTTTACGGTA-
TC-39
Product: 1637 bp
Right arm:
Genomic primer: 59- AGTCTGTATCTCACTACGGCATC-
C-39
Neo cassette primer: 59- TGCACGAGACTAGTGAGACGT-
G-39
Product: 3403 bp
Amplification of the inserted construct and digestion:
Genomic upstream primer: 59-CAGTCCTACCTTATCCAT-
GAGCAC-39
Genomic downstream primer: 59-AGTCTGTATCTCACTA-
CGGCATCC-39
Product: 4300 bp=construct without Neo cassette; NotI
digestionR2900 bp + 1300 bp
Product: 6109 bp=construct with Neo cassette; NotI diges-
tionR3100 bp + 2900 bp
Mice:
Whole construct
Set 1
Fw primer: 59-ATGGCACCACCCACAATAGG-39
Rev primer: 59-CCTAGCAACTGGTAACAGTGC-39
Product: 2027 bp with Neo cassette
Product: 332 bp without Neo cassette
Product: 194 bp wild type
Set2
Fw primer: 59-ATGGCACCACCCACAATAGG-39
Rev primer: 59-ggtaagctctaaggagaagcg-39
Product: 2500 bp with Neo cassette
Product: 849 bp without Neo cassette
Product: 704 bp wild type
Due to the specific sequences present in the amplified PCR
product, no digestion of the amplicon could be performed on the
mice PCR analysis. PCR products were thus sequenced to
ascertain that the targeted sequence was correctly inserted in the
genomic DNA. The sequence has been deposited in GenBank
(accession number GQ424832).
Southern Blot Analysis
Twenty mg of genomic DNA was digested with BamHI
overnight, run on a 1% TAE agarose gel and transferred on a
Hybond-N+ membrane (Amersham).
The probe was prepared by PCR from a BAC clone (RP24)
with the following primers:
-Left arm:
Fw: 59- GACAGAGGTTCTGCCCTCAG-39
Rev: 59-ACCGAGTCGTAGGACAGTG-39
Probe size: 547 bp
-Right arm:
Fw: 59- CTGTGCTGCCTGACACTACTTC-39
Rev: 59- TCTGTCCATACTCCCTGTCCTT-39
Probe size: 515 bp.
One mg of PCR probe was labelled with 5 mLo f
32P-dCTP
(3000 Ci/mmol, ICN) and purified through a Push Column
(Stratagene) according to the manufacturer’s protocol. Membranes,
containing the cleaved genomic DNA, were hybridized at 65uCa n d
subsequently washed 4 times in SSC buffer (Sigma). Film was
exposed to the hybridised membranes at –80uC and then developed.
General Pathology Analysis
Wild-type and FDDKI animals were studied at 18 months of
age. After anesthesia, animals were perfusion-fixed with 4%
paraformaldehyde in 0.1 M phosphate buffer (pH 7.2) (Sigma),
after which brains and organs were removed, embedded in
paraffin and sectioned. Eight mm sections were cut and mounted
on poly-l-lysine-coated slides. After deparaffinization in Xylene ad
rehydration, sections were stained with hematoxylin and eosin
(H&E), Congo red standard methods. Mineralization was
visualized in H&E sections as a deep basophilic amorphous
and/or granular material.
Brain Histology and Immunohistochemistry
Wild-type, FDDKI and FDD-Tg animals were studied at 18
months of age. After anesthesia, animals were perfusion-fixed with
4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.2)
(Sigma), after which brains were removed, embedded in paraffin
and sectioned. Eight mm sections were cut and mounted on poly-l-
lysine-coated slides. Sections were stained with H&E, Congo red
and Thioflavin S (ThS) methods. Immunohistochemical stainings
were carried out as described [20] with following primary
antibodies: glial fibrillary acidic protein (GFAP) (Dako, Carpin-
teria, CA); ubiquitin (Dako); amyloid b protein (Ab) clone 4G8
(SIGNET, Dedham, MA); and ADan amyloid peptide (Ab 1700)
[20]. Immunostaining was visualized using the avidin-biotin
system (Vectastain; Vector Laboratories, Burlingame, CA) and
3,39-diaminobenzidine (Sigma) as the chromogen. The sections
were counterstained with cresyl violet or H&E. ADan transgenic
(FDD-Tg) mice were described elsewhere [20].
Neuronal Cultures
Neuronal cultures of FDDKI mice, and wt littermates, were
performed as described previously [22,23] from E16-17 fetuses.
Western Blot
Western blot was conducted on protein extracts from brains or
neuronal culture of FDDKI mice and wt littermates, as described
previously [5] for cells lysates and brain tissue. Briefly, primary
neuronal cells were lysed in Hepes-Triton buffer (20 mM Hepes/
NaOH pH 7.4, 1 mM EDTA, 150 mM NaCl, 0.5% Triton X-
100, plus protease inhibitors (PIs)) on ice for 30 min. The lysates
were cleared by spinning at 20,000 g for 10 min. Equal amount of
proteins of cleared lysates were loaded on SDS-PAGE and
transfered onto nitrocellulose membranes; APP and BRI2 (wild
type and Danish mutants) were detected by 22C11 (Chemicon,
MAB348) or BRI2 antibody, generously provided by Dr. Haruhiko
Akiyama, respectively [24].
Results
Generation and Characterization of FDDKI Mice
The targeting strategy for the generation of the Danish mutant
FDDKI mice entailed the replacement of the BRI2 exon 6 with a
mutated exon 6 carrying the FDD mutation. We generated a
FDD Knock-In Mice
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vector used the floxed PGK-neo selection cassette and contains a 59
homologous region and the negative selection cassette, PGK-dt.
The 39 homologous region introduced the FDD mutation and a
BamHI site into the BRI2 mouse gene. The 10 nucleotide insertion
found in patients with FDD was introduced before the stop codon.
In order to humanize the mouse C-terminal region of BRI2,a n
alanine (A) was substituted for threonine (T) at codon 250 (Fig. 1a)
of the murine BRI2 gene.
The linearized targeting vector was transfected into 129 ES cells
by electroporation. In the presence of the positive selection drug,
G418, only those clones in which the PGK-neo selection cassette
was integrated and the PGK-dt cassette was removed by
homologous recombination would survive. ES cell clones carrying
the targeting vector by random, non-homologous integration,
were eliminated due to expression of diphtheria toxin.
After selection in G418-containing medium, ES cell clones
carrying the proper homologous recombination and the tADan
(targeted ADan) allele were identified by PCR for 59 region (i.e. Left
Arm: if homologous recombination had occurred these primers
would amplify a product of 1.67 kb) and for the 39 region (i.e. Right
Arm: if homologous recombination had occurred these primers
would amplify a product of 3.4 kb). Out of the ,600 screened ES
clones, we found three clones in which the Danish mutation was
inserted in one of the BRI2 alleles. Representative positive
(BRI2
tADan/+344 and BRI2
tADan/+339) and negative (BRI2
tADan/+342)
ES clones are shown in Fig. 1b. Also, PCR amplification and
digestion, as specified in the Material and Methods section, was
used to check the proper insertion of the construct in the genomic
DNA and the removal of the Neo cassette (not shown).
The occurrence of homologous recombination was confirmed
by sequencing the PCR products and by performing Southern blot
analysis (Fig. 1c). DNA derived from individual BRI2
tADan/+ ES
clones was digested with BamHI, gel separated, blotted into a nylon
membrane and hybridized with either the 59 or the 39probe. The
59 probe hybridizes with a ,11.9 kb fragment derived from the
wild-type locus. Homologous recombination at the 59 homologous
region yields a ,8.9 kb fragment upon BamHI digestion due to the
introduction of the BamHI site and the PGK-neo selection cassette.
ES clones BRI2
ADan/+344 and BRI2
ADan/+339 carry a wild type
allele (11.9 kb) and a recombined allele (8.9 kb). Of note, the
11.9 kb and 8.9 kb bands had a similar intensity, indicating that
50% of the BRI2 alleles are wild type and 50% are recombined,
and proving that the ES cells we have selected are a clonal
populations. Similar results were obtained when homologous
recombination at the 39 site was assessed. In this case the 39 probe
detected a wild-type ,11.9 kb fragment and a recombinant 4.7 kb
fragment, due to the introduction of the BamHI site.
Figure 1. Generation of FDDKI mice. 1a. Schematic representation of the construct that was injected in 129 ES cells, showing site of ADan
mutation on Exon 6, primer sites, site of Southern Blot probe, LoxP, pgk-dt and pgk-Neo sites. The bottom graphics depict the construct with and
without the pgk-Neo cassette that has been removed by means of Cre recombinase. 1b. Examples of 2 ES clones positive for the homologous
recombination of the mutated allele: left arm (a–c: 1.67 kb) and right arm (b–d: 3.4 kb) PCRs are shown. 1c. Southern Blot showing a shift from the
11.9 kb of the wild type genome to the 8.9 kb band of the FDD KI mice, due to the insertion of a new BamHI site. KI mice show both bands, indicating
heterozygosity.
doi:10.1371/journal.pone.0007900.g001
FDD Knock-In Mice
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carrying the correct site-specific homologous recombination, were
injected into C57BL/6J blastocysts (black coat colour) at the Albert
Einstein College of Medicine gene-targeting facility. The resulting
chimeras with a high proportion of agouti coat colour (i.e. with a
high relative contribution from the injected ES cells) were back-
crossed to C57BL/6J mice to obtain heterozygous BRI2
ADan/wt,
which were identified by PCR and Southern analysis as described
above (not shown) using tail DNA. Heterozygous mice were crossed
to Meu40-Cre mice to obtain Meu40/BRI2
tADan/wt animals. Cre is a
bacteriophage P1-encoded recombinase that catalyzes site-specific
recombination between two 34 bp loxP recognition sites, resulting
in the excision of the intervening DNA sequences. The resulting
mouse has been named FDDKI.
General Characteristics and Pathology of the FDDKI Mice
Mice presented with no growth abnormalities, thrived at
appropriate age, as their wild type littermates. Up to age 18
months, no susceptibility to infections was noted. The animals are
active and alert.
Before the pathology examination, at 18 months of age, they
presented in good body condition with adequate body fat, with no
discharges or secretions from nostrils, conjunctiva, aural, urogenital
or anal openings. Some mice also presented heart valve melanosis,
which is a common finding in aged mice of various strains. Other
sporadic findings, which are common in aged mice, were small foci
of hepatocellular necrosis, vacuolation of and degeneration/
regeneration of kidney tubular epithelial cells, mineralization in
the kidney tubules in the pelvis and cortico-medullary junction (not
shown). Overall, these mice have lesions that are commonly found
in older mice and are considered age-related, spontaneous lesions.
All of the lesions found were considered to be within the normal
limits for age-related lesions. One of the animals presented with a
uterine histiocytic sarcoma and hydronephrosis, both of which are
found in older, untreated mice at low incidence.
Neuropathology
A few animals presented a small amount of dark basophilic
material deposited on either side of the lateral thalamus consistent
with mineralization (incidental, Fig. 2d), which is a common
finding in aged mice of various strains, and the deposits develop
along the basement membranes of the vasculature and may
contain calcium and phosphorus. The finding of dark brown
pigment along the meninges of the olfactory bulbs is consistent
with melanosis (incidental, Fig. 2a), which is also a common
finding in mice in dark pigment mouse strains such as C57BL/6 or
having that strain the their background. All the brain tissue and
the spinal cord were stained with Congo red for potential amyloid
deposition. All of the stained tissue was negative for amyloid (not
shown). Samples of H&E staining of cerebral cortex, hippocam-
pus, cerebellum, thalamus and spinal cord are shown in Fig. 2a–e.
Brain sections of 18-month-old mice were examined for FDD-
related pathology, particularly for amyloid deposition in brain
parenchyma and vessel walls. For comparison, we included
sections of an age-matched female FDD-Tg mouse, which
expresses the Danish mutant form of human BRI2 under the
mouse prion protein promoter [20]. H&E staining of Knock In
mice (Fig. 3c, 4a) showed no significant loss of neurons or
Figure 2. General Neuropatholgy. H&E staining of 18 month old FDDKI mice showing signs of melanosis in the meninges of olfactory bulb (a) and
signs of mineralization in the thalamus (d). The remaining parenchyma of brain cortex and hippocampus (b), cerebellum (c) and spinal cord (e) show
normal cellular structures.
doi:10.1371/journal.pone.0007900.g002
FDD Knock-In Mice
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confirmed when mutant sections were compared with those of
wild type littermates (Fig. 3a, 4d). Immunostaining using anti-
GFAP (Fig. 3b, d) and anti-ubiquitin (not shown) antibodies did
not reveal significant differences with wild type mice in levels of
activated astrocytes or presence of ubiquitinated material,
respectively. Staining using Congo red or ThS did not show the
presence of amyloid deposits (Fig. 4b). Amyloid deposition in
FDD-Tg mice is particularly strong in the cerebellum (Fig. 4e) but
not in Knock In mice (Fig. 4b) and only FDD-Tg mice showed
immunoreactivity using Ab 1700, specific for the ADan amyloid
peptide [20] (Fig. 4f versus 4c). Immunoreactivity was not seen in
non-transgenic littermates, FDD-Tg and Knock In mice using
antibody 4G8 (not shown). These results indicated that the brain
of Knock In mice maintained normal morphology of aged mice
and were free of amyloid deposits at 18 months of age.
Biochemical Analysis of BRI2-ADan Expression
To determine whether the mutant proteins are expressed in vivo,
we made protein extracts form neuronal cultures of wt, BRI2
ADan/wt
and BRI2
ADan/ADan mice. Western blot analysis of these samples
shows three phenomenona. 1) A common, major band of about
32 kDa is readily visible in all three samples. This band
corresponds to the post-furin cleavage mature BRI2 (mBRI2)
polypeptide because mBRI2 is identical regardless of whether it is
derived from the wild type or the mutant precursor protein. 2) A
much less abundant protein of ,33 kDa which is visible in the
wild type and BRI2
ADan/wt sample but not the BRI2
ADan/ADan lysate.
This band corresponds to the wild type, immature BRI2 precursor
(imBRI2). The absence of this band in the BRI2
ADan/ADan neurons is
attributable to the fact that these cells have both BRI2 alleles
mutated. 3) As expected, the BRI2
ADan/wt sample expresses all three
BRI2 polypeptides, i.e. wild type imBRI2, BRI2-ADan precursor
and mBRI2. It is worth noting that, while immature murine BRI2
(imBRI2) is barely detectable, BRI2-ADan is more markedly
expressed (see BRI2
ADan/ADan neurons, Figure 5) in this specific
experiment. Whether this is related to the artificial absence of the
wild type protein (this does not happen in FDD since the patience
have only one mutated allele) or reflects some interesting biology
of BRI2-ADan, remains to be determined. Notably, APP expression
and maturation are comparable in FDDKI and wt mice (Fig. 5,
lower panel).
Discussion
In this manuscript we present an initial characterization of a
Knock In model for a human neurodegenerative disorder, FDD.
This Knock In model is strategically different from the
conventional genetic approach to cerebral amyloidosis. Tradition-
ally, mouse models for human dementias are based on a transgenic
approach in which human mutant proteins that cause familial
forms of dementia are over-expressed under the control of brain-
specific promoters [25,26,27]. This approach has both limitations
and advantages. The potential limitations are linked to the fact
that these models are genetically incongruous with the human
diseases. These dementias have an autosomal dominant way of
transmission and affected subjects have a wild type and a mutant
allele. On the contrary, the commonly used animal models over-
express, from an artificial promoter, several copies of a mini-gene
coding the mutant protein. The mutant gene is therefore expressed
in a spatio-temporal manner different from the natural alleles and
in cells with two copies of wild type alleles. However, transgenic
Figure 3. Sections of the hippocampus of FDDKI mice. Sections from a wild type (a, b) and a homozygous knock-in mouse (c, d) were stained
with H&E (a, c). Sections were also studied by immunohistochemistry using anti-GFAP (b, d). No significant differences were observed between wild-
type and Knock In mice. Scale bars: a–d, 200 mm.
doi:10.1371/journal.pone.0007900.g003
FDD Knock-In Mice
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mice, and the reproduction of those lesions is one of the main
parameters used to endorse an animal model as representative of
the human disease. The opposite is true for a Knock In approach.
In this genetic paradigm, the pathogenic human mutation is
inserted in the mouse allele. Thus, the Knock In mouse is
genetically faithful to the human pathology. However, the Knock
In model may not successfully reproduce the amyloid lesion in the
mouse. The model that we present here is a clear demonstration of
the above-mentioned assumptions. A comparison of the FDD-KI
model that we have created with the FDD transgenic model
generated by Vidal et al [20] illustrates the superior power of a
transgenic approach as far as the reproduction of amyloidogenic
lesions are concerned.
In spite of this limitation, we believe that there is some merit to a
Knock In approach. Human familial dementias may have a
pathogenic component due to loss of function caused by the
mutation [28,29,30,31,32]. This component may participate to the
pathogenic process together with a gain of toxic function due to
amyloidosis. A loss of function phenotype would be hidden by a
transgenic approach for two reasons: 1) the two endogenous wild
type alleles can support synthesis of sufficient amounts of
functional wild type protein: 2) the over-expression of a partial
loss of function mutant protein may augment rather then decrease
that function, as may happen in the disease. It would be erroneous
to assume that the absence of obvious neuropathological lesions
(such as plaques, NFTs and/or neuronal cell loss) indicate absence
of clinical pathology. Functional deficits may underlie the very first
clinical manifestations of neurodegenerative diseases, and memory
deficits may be caused not by gross anatomical changes but by
subtle dysfunctions of the neuronal network. In this framework,
determining the absence of neuropathological lesions in FDDKI
mice is intrinsically important. The behavioral characterization of
this mouse model will test this hypothesis. In addition, the FDDKI
mouse will be useful to clarify the change of trafficking or
processing of Danish mutant of BRI2 protein without potential
artifacts due to over-expression in transgenic models. Finally, the
FDDKI mouse will be instrumental in studying the interaction
between mutant BRI2 and APP in vivo and how the Danish
mutation affects the inhibitory role of BRI2 on APP processing
in vivo.
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